Duvelisib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Duvelisib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 5 molecular targets, including PIK3CD, PIK3CG and Pik3cg. Recorded indications include Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma and Malignant lymphoma - small lymphocytic.

• Approval status: onp (first approved 2018 by the FDA).
• Molecular targets: PIK3CD, PIK3CG, Pik3cg and PIK3CB (5 listed in DrugCentral).
• Indications: Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma and Malignant lymphoma - small lymphocytic.
• ATC code: L01EM04 (Phosphatidylinositol-3-kinase (Pi3K) inhibitors).
• Molecular formula: C22H17ClN6O; molecular weight 416.87 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Chronic lymphoid leukemia, disease
• Follicular non-Hodgkin's lymphoma
• Malignant lymphoma - small lymphocytic

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	PIK3CD	inhibitor	Kd 10.64
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	PIK3CG	inhibitor	Kd 9.62
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Pik3cg	unknown	IC50 7.29
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	PIK3CB	inhibitor	IC50 7.07
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	PIK3CA	inhibitor	IC50 5.80

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-05-19	EMA	—	Verastem Europe GmbH
2018-09-24	FDA	—	VERASTEM INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01EM04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Phosphatidylinositol-3-kinase (Pi3K) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product use in unapproved indication	204.7
Prescribed underdose	117.5
Diarrhoea	64.1
Disease progression	34.0
Malignant neoplasm progression	34.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Duvelisib is on its molecule page.

• Molecular formula: C₂₂H₁₇ClN₆O
• Molecular weight: 416.87 g/mol
• CAS number: 1201438-56-3
• InChIKey: SJVQHLPISAIATJ-ZDUSSCGKSA-N
• PubChem CID: 50905713

C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Duvelisib used for?

DrugCentral lists the following indications for Duvelisib: Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma and Malignant lymphoma - small lymphocytic.

How does Duvelisib work?

Its molecular targets in DrugCentral include PIK3CD (inhibitor), PIK3CG (inhibitor), Pik3cg and PIK3CB (inhibitor).

When was Duvelisib first approved?

Duvelisib was first approved by the FDA in 2018.

What is the chemical formula of Duvelisib?

Duvelisib has the molecular formula C22H17ClN6O and a molecular weight of 416.87 g/mol.

Sources

• DrugCentral drug card 5296 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3039502 — compound record and bioactivity
• PubChem CID 50905713 — chemical identifiers
• DrugBank DB11952 — drug record
• FDA UNII 610V23S0JI — substance identity
• DailyMed: FDA labels for Duvelisib — current prescribing information (label search)
• UniProt O00329 (PIK3CD) — target protein
• UniProt P48736 (PIK3CG) — target protein
• UniProt P42338 (PIK3CB) — target protein
• UniProt P42336 (PIK3CA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.